CD19 and CD22 chimeric antigen receptors and uses thereof
US12344651B2 · kind B2 · utility
0Cited by
46References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2024 |
| Grant date | Jul 1, 2025 |
| Priority date | — |
| Expiry date | Mar 27, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/03
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.